deltatrials
Completed NCT00443443

A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

A Long-Term Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

Sponsor: Biogen

Conditions Rheumatoid Arthritis
Updated 8 times since 2017 Last updated: Mar 26, 2015 Started: Jan 31, 2007 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013

A observational or N/A phase clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Biogen and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2021 — Jul 2024 [monthly]

    Completed

  5. Jun 2018 — Jan 2021 [monthly]

    Completed

▶ Show 3 earlier versions

  1. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: PHASE4 → None

  2. Feb 2017 — Apr 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Biogen
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abilene, United States, Akron, United States, Albany, United States, Albuquerque, United States, Ann Arbor, United States, Ashland, United States, Austell, United States, Baltimore, United States, Battle Creek, United States, Beckley, United States and 162 more location s